Vineet Laboratories financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹10.4cr+39.7% on Q1 FY26
Net profit
₹1.5cr−₹0.9 cr in Q1 FY26
EBITDA margin
21.7%+17.4 pts on Q1 FY26
EPS
₹0.73−₹0.94 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue10.47.4+39.7%
EBITDA2.30.3+608.0%
EBITDA margin21.7%4.3%+17.4 pts
Profit before tax0.8−0.9—
Net profit1.5−0.9—
EPS₹0.73−₹0.94—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹10.4 crNet profit₹1.5 crNet margin14.6%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
69.3————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
16.716.70.30.20.6
45.345.340.044.331.1
97.9————
62.459.475.0151212
—−20.8%−50.2%−29.1%—
10.48.5−16.37.27.7
16.7%14.3%−21.7%4.8%3.6%
8.06.1−18.84.75.3
4.01.6−20.21.01.3
6.4%2.7%−26.9%0.7%0.6%
₹2.07₹0.84−₹10.51₹0.53₹0.65
—+107.9%−2,066.0%−18.0%—
—−12.211.5−11.4−9.6
—−1.2−1.0−0.2−7.6
−13.4−13.410.4−11.7−17.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VINEETLAB₹36.06

Vineet Laboratories Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMMANGALAMLASAKREBSBIOALPABALPHARMAORTINGLOBENATCAPSUQMcap ₹69.3 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————69.3
- Cash, Equiv & ST Investments0.60.20.316.716.7
+ Total Debt31.144.340.045.345.3
Enterprise Value————97.9
Revenue212.3150.675.059.462.4
Growth %, YoY—-29.1-50.2-20.8—
EBITDA7.77.2-16.38.510.4
Margin %3.614.78-21.7114.2716.70
EBIT5.34.7-18.86.18.0
Net Income1.31.0-20.21.64.0
Margin %0.590.68-26.922.706.39
EPS, Adj (current shares)0.650.53-10.510.842.07
Growth %, YoY—-18.0-2,066.0+107.9—
Cash from Operations-9.6-11.411.5-12.2—
Capital Expenditures-7.6-0.2-1.0-1.2—
Free Cash Flow-17.3-11.710.4-13.4-13.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Vineet Laboratories financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Vineet Laboratories (NSE: VINEETLAB) had a market capitalisation of ₹72.5 crore at the 29 October 2026 close (₹37.76 a share), a PE ratio of 18.2 on the last four quarters' profit and a price-to-book ratio of 1.59. In FY26 its consolidated net profit was ₹1.6 crore on revenue of ₹59.4 crore; in Q1 FY27 (April–June 2026) it was ₹1.5 crore. Its debt-to-equity ratio was 0.99 on 31 March 2026. Promoters held 5.98% of the shares on 30 September 2026.

Share price used
₹37.76 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Vineet Laboratories at a glance · consolidated

Market cap
₹72.5 Crat ₹37.76 · 29 Oct close
PE ratio (last 4 quarters)
18.245.2 on FY26 profit
Price to book (PB)
1.59book value ₹23.74 a share
ROE (FY26)
5.3%+87.1 pts vs FY25ROCE 15.6%
Debt to equity
0.99net debt ₹28.3 Cr
Promoter holding
5.98%unchanged vs 30 Jun 202630 September 2026
Net worth
₹45.6 Cr+211.3% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹13.4 Cr
EPS (FY26)
₹1.00

Questions

What is the Vineet Laboratories PE ratio today?

Vineet Laboratories' PE ratio is 18.2 at the 29 October 2026 close (₹37.76 a share): a market capitalisation of ₹72.5 crore divided by consolidated net profit of ₹4 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹1.6 crore) it is 45.2.

What is the Vineet Laboratories PB ratio (price to book value)?

Vineet Laboratories' price-to-book (PB) ratio is 1.59 at the 29 October 2026 close: a market capitalisation of ₹72.5 crore divided by shareholders' equity (book value) of ₹45.6 crore on 31 March 2026. That is a book value of ₹23.74 per share against a share price of ₹37.76.

What is the Vineet Laboratories debt to equity ratio?

Vineet Laboratories' debt-to-equity ratio was 0.99 on 31 March 2026: borrowings of ₹45.3 crore against total equity of ₹45.6 crore. A year earlier, on 31 March 2025, it was 2.73.

What is the Vineet Laboratories market cap?

Vineet Laboratories' market capitalisation was ₹72.5 crore at the 29 October 2026 close: 1.92 crore shares at ₹37.76 each.

Is Vineet Laboratories debt free?

No. Vineet Laboratories had borrowings of ₹45.3 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.99. Its cash and current investments were ₹17.1 crore, so its net debt was ₹28.3 crore.

What is the Vineet Laboratories EPS?

Vineet Laboratories' basic earnings per share (EPS) were ₹1.00 in FY26.

What is the Vineet Laboratories net worth?

Vineet Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹45.6 crore on 31 March 2026, up 211.3% from ₹14.6 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹72.5 crore at the 29 October 2026 close.

What is the Vineet Laboratories book value per share?

Vineet Laboratories' book value per share was ₹23.74 on 31 March 2026: shareholders' equity of ₹45.6 crore divided by the 1.92 crore shares in issue. The share price at the 29 October 2026 close was ₹37.76.

What is the Vineet Laboratories promoter holding?

Promoters held 5.98% of Vineet Laboratories on 30 September 2026, unchanged from the previous quarter and down 9.91 percentage points from 15.89% a year earlier, according to the shareholding pattern filed with NSE.

What is the Vineet Laboratories ROE and ROCE?

In FY26, Vineet Laboratories' return on equity (ROE) was 5.3% and its return on capital employed (ROCE) was 15.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −81.8% and ROCE −61.6%.

What is the Vineet Laboratories free cash flow?

In FY26, Vineet Laboratories generated ₹12.2 crore of cash from operations and spent ₹1.2 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹13.4 crore. In FY25 it was ₹10.4 crore.

What are the Vineet Laboratories latest quarterly results?

Vineet Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 25 August 2026: consolidated net profit ₹1.5 crore, against a loss of ₹87 lakh in Q1 FY26; revenue from operations ₹10.4 crore, up 39.7% year on year.

What is the Vineet Laboratories shareholding pattern?

On 30 September 2026, Vineet Laboratories' shares were held by promoters 5.98%, foreign portfolio investors (FII/FPI) 0.24% and retail and other non-institutional investors 93.78%.

What is the Vineet Laboratories revenue and profit in FY26?

In FY26 (April 2025–March 2026), Vineet Laboratories' consolidated net profit was ₹1.6 crore, against a loss of ₹20.2 crore in FY25, on revenue from operations of ₹59.4 crore (down 20.8%). Over three years, from FY23, net profit was up 28.1%.

When are the Vineet Laboratories next results?

Vineet Laboratories has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does Vineet Laboratories compare with its peers?

On FY26 consolidated figures, against Biofil Chemicals & Pharmaceuticals, Mangalam Drugs And Organics and Lasa Supergenerics: Vineet Laboratories' operating margin of 10.2% is the highest of the four (Biofil Chemicals & Pharmaceuticals 1.3%, Mangalam Drugs And Organics −14.3%, Lasa Supergenerics −136.9%; peer average −49.9%); its return on equity of 5.3% is the second highest of the four (Biofil Chemicals & Pharmaceuticals 13.8%, Mangalam Drugs And Organics −35.2%, Lasa Supergenerics −51.1%; peer average −24.2%).

Vineet Laboratories vs Biofil Chemicals & Pharmaceuticals: how do they compare?

In FY26, Vineet Laboratories earned net profit of ₹1.6 crore on revenue of ₹59.4 crore, against ₹2.8 crore on ₹28.4 crore for Biofil Chemicals & Pharmaceuticals. Vineet Laboratories' operating margin was 10.2% (Biofil Chemicals & Pharmaceuticals 1.3%) and its return on equity 5.3% (Biofil Chemicals & Pharmaceuticals 13.8%). At the 29 October 2026 close, Vineet Laboratories' market capitalisation was ₹72.5 crore against ₹47.9 crore for Biofil Chemicals & Pharmaceuticals, and its PE ratio on FY26 profit 45.2 against 17.2.

Where do these Vineet Laboratories figures come from?

From Vineet Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.